Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25

Rhea-AI Summary

Biocept, Inc. (NASDAQ: BIOC) has announced that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum on August 25 at 1:00 p.m. Eastern time. The event will feature a company overview followed by a Q&A session. Biocept specializes in liquid biopsy tests that provide clinically actionable information for cancer treatment, utilizing its patented Target Selector™ technology for analyzing tumor markers. The company has also expanded its services to include COVID-19 testing to aid in the pandemic response.

SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the Proactive One2One Virtual Investor Forum, North America on Tuesday, August 25 at 1:00 p.m. Eastern time (10 a.m. Pacific time). 

The virtual event will include a brief company overview followed by a fully interactive Q&A session.  The live event can be accessed here and will be archived on the Investor Relations section of the Biocept website.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in circulating tumor DNA (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. In addition, Biocept recently added COVID-19 testing to support efforts to fight the pandemic. For additional information, please visit www.biocept.com.

Investor Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com 
310-691-7100

FAQ

When is Biocept's presentation at the Proactive One2One Virtual Investor Forum?

Biocept's presentation is scheduled for August 25 at 1:00 p.m. Eastern time.

What is the purpose of the Proactive One2One Virtual Investor Forum?

The forum aims to provide a company overview and an interactive Q&A session for investors.

What technology does Biocept use for its liquid biopsy tests?

Biocept employs the patented Target Selector™ technology to analyze tumor-associated molecular markers.

What types of cancers does Biocept's liquid biopsy technology target?

Biocept's technology is designed for lung, breast, gastric, colorectal, prostate cancers, and melanoma.

Has Biocept expanded its testing services recently?

Yes, Biocept has recently added COVID-19 testing to support pandemic response efforts.